Key facts
- Fusion Genomics’s last known valuation is $36.7M (Dec 2021).
- It has raised $15.4M; the latest was Later Stage VC in Jan 2025.
- Notable investors include CELS Valley Ready, CQDM, VentureLabs, WUTIF Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Fusion Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Fusion Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fusion Genomics
Operator of a molecular diagnostics company intended to transform infectious diseases through advanced genomic technologies. The company develops molecular diagnostics specializing in next-generation sequencing for the medical, agriculture, and environmental monitoring sectors, enabling researchers to prevent unnecessary deaths from infectious diseases and halt the growing problem of drug resistance.
- Sector
- Healthcare
- HQ
- Richmond, Canada
- Founded
- 2013
- Employees
- 12
- Website
- fusiongenomics.com/
- Ownership
- Privately Held (backing)
Fusion Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fusion Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fusion Genomics in its N-PORT filings yet. We sweep new filings monthly.